194 related articles for article (PubMed ID: 24522405)
1. Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP).
Kitagawa Y; Ueno S; Izumi K; Mizokami A; Hinotsu S; Akaza H; Namiki M
J Cancer Res Clin Oncol; 2014 Apr; 140(4):673-9. PubMed ID: 24522405
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
Kitagawa Y; Ueno S; Izumi K; Kadono Y; Mizokami A; Hinotsu S; Akaza H; Namiki M
World J Urol; 2016 Mar; 34(3):319-27. PubMed ID: 26089252
[TBL] [Abstract][Full Text] [Related]
3. Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis.
Sasaki T; Onishi T; Hoshina A
Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):248-52. PubMed ID: 21502970
[TBL] [Abstract][Full Text] [Related]
4. Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer.
Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
BMC Urol; 2014 Apr; 14():33. PubMed ID: 24773608
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer.
Hori S; Jabbar T; Kachroo N; Vasconcelos JC; Robson CN; Gnanapragasam VJ
J Cancer Res Clin Oncol; 2011 Feb; 137(2):235-41. PubMed ID: 20390426
[TBL] [Abstract][Full Text] [Related]
6. Cutoff value of time to prostate-specific antigen nadir is inversely correlated with disease progression in advanced prostate cancer.
Sasaki T; Onishi T; Hoshina A
Endocr Relat Cancer; 2012 Oct; 19(5):725-30. PubMed ID: 22807499
[TBL] [Abstract][Full Text] [Related]
7. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
Choueiri TK; Xie W; D'Amico AV; Ross RW; Hu JC; Pomerantz M; Regan MM; Taplin ME; Kantoff PW; Sartor O; Oh WK
Cancer; 2009 Mar; 115(5):981-7. PubMed ID: 19152438
[TBL] [Abstract][Full Text] [Related]
8. Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer.
Hamano I; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
World J Urol; 2019 Nov; 37(11):2365-2373. PubMed ID: 30729312
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
[TBL] [Abstract][Full Text] [Related]
10. The slope associated with nadir prostate-specific antigen is prognostically significant in men with hormone-sensitive prostate cancer after primary androgen deprivation therapy.
Zhenhao Z; Xiaofeng C; Hao J; Ming Y; Hongtao Z; Wenrui H; Cheng Z; Xiaochen Z; Gongxian W
Cancer Med; 2022 Sep; 11(17):3251-3259. PubMed ID: 35307955
[TBL] [Abstract][Full Text] [Related]
11. Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.
Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
BMC Cancer; 2015 May; 15():420. PubMed ID: 25990314
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
Stewart AJ; Scher HI; Chen MH; McLeod DG; Carroll PR; Moul JW; D'Amico AV
J Clin Oncol; 2005 Sep; 23(27):6556-60. PubMed ID: 16170163
[TBL] [Abstract][Full Text] [Related]
13. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.
Wu KJ; Pei XQ; Tian G; Wu DP; Fan JH; Jiang YM; He DL
Asian J Androl; 2018; 20(2):173-177. PubMed ID: 28905815
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer.
Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Orsola A; Planas J; Catalán R; Reventós J
Int J Biol Markers; 2005; 20(4):209-16. PubMed ID: 16398402
[TBL] [Abstract][Full Text] [Related]
15. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738
[TBL] [Abstract][Full Text] [Related]
16. Time to Prostate-specific Antigen Nadir and the Risk of Death From Prostate Cancer Following Radiation and Androgen Deprivation Therapy.
Pike LRG; Wu J; Chen MH; Loffredo M; Renshaw AA; Pfail J; Kantoff PW; D'Amico AV
Urology; 2019 Apr; 126():145-151. PubMed ID: 30664895
[TBL] [Abstract][Full Text] [Related]
17. Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy.
Huang SP; Bao BY; Wu MT; Choueiri TK; Goggins WB; Liu CC; Huang CY; Pu YS; Yu CC; Wu TT; Huang CN; Huang CH; Wu WJ
Aging Male; 2012 Mar; 15(1):34-41. PubMed ID: 21615239
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
Akakura K; Tsuji H; Suzuki H; Ichikawa T; Ishikawa H; Okada T; Kamada T; Harada M; Tsujii H; Shimazaki J
Jpn J Clin Oncol; 2014 Apr; 44(4):360-5. PubMed ID: 24585931
[TBL] [Abstract][Full Text] [Related]
19. Survival outcomes of Chinese metastatic prostate cancer patients following primary androgen deprivation therapy in relation to prostate-specific antigen nadir level.
Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
Asia Pac J Clin Oncol; 2017 Apr; 13(2):e65-e71. PubMed ID: 25471685
[TBL] [Abstract][Full Text] [Related]
20. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]